

Ataxia-telangiectasia - Pipeline Insight, 2021

<https://marketpublishers.com/r/A975A55FCF8EEN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: A975A55FCF8EEN

Abstracts

This report can be delivered to the clients within 24 hours

DelveInsight's, "Ataxia-telangiectasia - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Ataxia-telangiectasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Ataxia-telangiectasia Understanding

Ataxia-telangiectasia: Overview

Ataxia telangiectasia (AT) is a complex genetic neurodegenerative disorder that may become apparent during infancy or early childhood. Classic AT is characterized by a constellation of clinical symptoms including progressive ataxia, oculocutaneous telangiectasias and sinopulmonary disease and is usually associated with absence of ATM protein. Affected children typically develop difficulty in walking, problems with balance and hand coordination, involuntary jerking movements (chorea), muscle twitches (myoclonus), and disturbances in nerve function (neuropathy). Other laboratory features associated with AT include elevated serum levels of alpha-fetoprotein (AFP) and increased chromosomal breakage with in vitro exposure to ionizing radiation. Treatment for AT is directed toward control of symptoms. For respiratory infections,

therapy with an antibiotic drug, postural drainage (with the head lower than the rest of the body) of the bronchial tubes and lungs, and gammaglobulin injections in some cases may be effective.

'Ataxia-telangiectasia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ataxia-telangiectasia pipeline landscape is provided which includes the disease overview and Ataxia-telangiectasia treatment guidelines. The assessment part of the report embraces, in depth Ataxia-telangiectasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ataxia-telangiectasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ataxia-telangiectasia R&D. The therapies under development are focused on novel approaches to treat/improve Ataxia-telangiectasia.

Ataxia-telangiectasia Emerging Drugs Chapters

This segment of the Ataxia-telangiectasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ataxia-telangiectasia Emerging Drugs

GTX-102: Acasti Pharma

GTX-102 is a novel and convenient oral mucosal spray formulation of betamethasone intended to significantly improve neurological symptoms of A-T, including improving clinical assessments of posture and gait disturbance, and kinetic speech and oculomotor functions. The drug is in Phase III clinical studies for the treatment of Ataxia-

telangiectasia.

IB1001: IntraBio

IB1001 (N-Acetyl-L-Leucine) is an orally administered small molecule, calcium channel modulator and modified amino acid. IntraBio is developing IB1001 for other neurodegenerative diseases and lysosomal storage disorders. The drug is in Phase II clinical studies for the treatment of Ataxia-telangiectasia.

Further product details are provided in the report.....

Ataxia-telangiectasia: Therapeutic Assessment

This segment of the report provides insights about the different Ataxia-telangiectasia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ataxia-telangiectasia

There are approx. 4+ key companies which are developing the therapies for Ataxia-telangiectasia. The companies which have their Ataxia-telangiectasia drug candidates in the most advanced stage, i.e. Phase III include, Acasti Pharma.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Ataxia-telangiectasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ataxia-telangiectasia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ataxia-telangiectasia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ataxia-telangiectasia drugs.

Ataxia-telangiectasia Report Insights

Ataxia-telangiectasia Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Ataxia-telangiectasia Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Ataxia-telangiectasia drugs?

How many Ataxia-telangiectasia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ataxia-telangiectasia?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ataxia-telangiectasia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Ataxia-telangiectasia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Acasti Pharma

EryDel

IntraBio

Matrix Biomed

Key Products

GTX-102

Ery-Dex

IB1001

MBM-01

Contents

Introduction

Executive Summary

Ataxia-telangiectasia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Ataxia-telangiectasia – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

GTX-102: Acasti Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Mid Stage Products (Phase II)

Comparative Analysis

IB1001: IntraBio

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report

Early Stage Products (Phase I/II)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report
Preclinical/Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Ataxia-telangiectasia Key Companies
Ataxia-telangiectasia Key Products
Ataxia-telangiectasia- Unmet Needs
Ataxia-telangiectasia- Market Drivers and Barriers
Ataxia-telangiectasia- Future Perspectives and Conclusion
Ataxia-telangiectasia Analyst Views
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Ataxia-telangiectasia

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Ataxia-telangiectasia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Ataxia-telangiectasia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/A975A55FCF8EEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A975A55FCF8EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970